Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study.
OBJECTIVE
To evaluate the incidence and severity of apnoea and bradycardia in hospitalized preterm infants following immunization at 2 months of age, and identify risk factors.


METHODS
A prospective study of 98 preterm infants, of gestational age 24-31 weeks, immunized at approximately 2 months post natal age with diphtheria-tetanus-whole cell pertussis vaccine (DTPw) in the neonatal intensive care unit (NICU) at King George V Hospital Sydney. Half the infants also received Haemophilus influenzae type b conjugate vaccine (Hib) simultaneously. All infants were monitored for apnoea and bradycardia in the 24 h periods pre- and post immunization.


RESULTS
Only one infant had apnoea and/or bradycardia pre-immunization compared with 17 post immunization. For 12 infants these events were brief, self-limiting and not associated with desaturations (oxygen saturation < 90%). However, for five infants (30%) these events were associated with oxygen desaturation and two of these infants required supplemental oxygen. The group that had apnoea and/or bradycardia and the group that did not were not significantly different in terms of gestational age, birth weight and other variables. Infants who received Hib together with DTPw were less likely to have apnoea and/or bradycardia than those given DTPw alone.


CONCLUSIONS
When considering immunization for preterm infants, the benefits of early immunization must be balanced against the risk of apnoea and bradycardia. We recommend that the cardio-respiratory function of hospitalized infants born at less than 31 weeks gestation be monitored for 48 h post immunization.
Botham
S J
SJ
Australian Centre for Immunization Research, New Children's Hospital, Westmead, Australia.
Isaacs
D
D
Henderson-Smart
D J
DJ
D001049:Apnea / Q000453:epidemiology / Q000209:etiology*; D001724:Birth Weight; D001919:Bradycardia / Q000453:epidemiology / Q000209:etiology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects*; D005260:Female; D018073:Haemophilus Vaccines / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D011446:Prospective Studies
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines